Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 9,241,910

« Back to Dashboard
Patent 9,241,910 protects DEXILANT SOLUTAB and is included in one NDA. There is one tentative approval for the compound protected by this patent. Additional details are available via the generic ingredient links below.

This patent has thirty patent family members in twenty-five countries.

Summary for Patent: 9,241,910

Title:Orally-disintegrating solid preparation
Abstract: The present invention provides an orally-disintegrating solid preparation such as a tablet produced by tabletting fine granules showing controlled release of a pharmaceutically active ingredient and an additive, and the like, and the orally-disintegrating solid preparation containing fine granules coated with a coating layer containing a polymer affording a casting film having an elongation at break of about 100-about 700%. With the preparation, breakage of fine granules during tabletting can be suppressed in the production of an orally-disintegrating solid preparation containing fine granules showing controlled release of a pharmaceutically active ingredient.
Inventor(s): Kurasawa; Takashi (Osaka, JP), Watanabe; Yasuko (Osaka, JP), Omachi; Yoshihiro (Osaka, JP)
Assignee: Takeda Pharmaceutical Company Limited (Osaka, JP)
Application Number:12/921,731
Patent Claim Types:
see list of patent claims
Formulation; Compound; Dosage form; Delivery;
Patent Metrics:
Source: PatentQuant.com
Field: Not categorized
Back Citations: 69th percentile
Forward Citations: 0th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Takeda Pharms Usa
TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL208056-001Jan 26, 2016RXYes9,241,910Mar 10, 2029Y
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 9,241,910

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2008-061673Mar 11, 2008
Japan2008-334920Dec 26, 2008
PCT Information
PCT FiledMarch 10, 2009PCT Application Number:PCT/JP2009/054983
PCT Publication Date:September 17, 2009PCT Publication Number: WO2009/113703

International Patent Family for Patent: 9,241,910

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina070863► subscribe
Australia2009224254► subscribe
BrazilPI0909439► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.